On 15th May, 2026, the People’s Republic of China (PRC) is set to implement the most significant overhaul of its Drug Regulatory Framework in over two decades. Beijing signals a departure from its generic orientation of chemical drug production. This article analyses the technical mechanisms of the “Regulations for the Implementation of the Drug Administration Law of the People’s Republic of China” (State Council Decree No. 828), the global pharmaceutical and geopolitical dri